The emerging role of immunotherapy in colorectal cancer.
Modulation of the interaction between the immune system and the tumor microenvironment has long been a target of cancer research, including colorectal cancer (CRC). Approaches explored to date include vaccines (autologous, peptide, dendritic cell, viral and bacterial), cytokine therapy, toll-like receptors (TLRs), autologous cell therapy and checkpoint inhibition. Until recently these approaches have been shown to have only modest efficacy in reducing tumor burden. However, significant breakthroughs have been made, with the use of checkpoint inhibitors targeting programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4). Immunotherapy now represents a possible avenue of curative treatment for those with chemo-otherwise refractory tumors. Success with this approach to immunotherapy has largely been confined to tumors with high mutational burdens such as melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer. This observation led to the exploration and successful use of checkpoint inhibitors in those with mismatch repair colorectal cancer which have a relatively high mutational burden. Ongoing trials are focused on further exploring the use of checkpoint inhibitors in addition to investigating the various combinations of immunotherapeutic drugs.
Department of Internal Medicine, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA ;
David
D
Lynch
Department Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
Adrian
A
Murphy
Colorectal cancer (CRC); autologous cell therapy; checkpoint inhibition; immunotherapy; toll-like receptors (TLRs); vaccines cytokine therapy
Nature. 2014 Nov 27;515(7528):563-7
25428504
J Clin Immunol. 2012 Aug;32(4):848-54
22371291
N Engl J Med. 2013 Jul 11;369(2):122-33
23724867
J Exp Med. 2000 Dec 4;192(11):1535-44
11104796
Ann Oncol. 2006 Jun;17(6):974-80
16600979
Clin Med Insights Oncol. 2012;6:19-30
22253552
Cancer Prev Res (Phila). 2013 Jan;6(1):18-26
23248097
Lancet. 2013 Jan 26;381(9863):303-12
23177514
Cancer Immunol Immunother. 2014 Mar;63(3):225-34
24327292
J Exp Med. 1996 Jan 1;183(1):283-7
8551233
Immunity. 2013 Jul 25;39(1):38-48
23890062
Mol Ther. 2011 Mar;19(3):620-6
21157437
Eur J Cancer. 2015 Jan;51(2):146-56
25480557
N Engl J Med. 2012 Jun 28;366(26):2443-54
22658127
J Clin Oncol. 2000 Jan;18(1):148-57
10623705
Clin Cancer Res. 2013 Sep 15;19(18):4917-24
23868869
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
24639052
Breast Cancer Res Treat. 2000 Mar;60(2):107-15
10845273
J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24
24816725
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14
11427731
Clin Cancer Res. 1999 Jun;5(6):1331-8
10389916
Cancer Immunol Immunother. 1992;35(5):325-30
1394336
Mol Ther. 2010 Apr;18(4):843-51
20179677
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
21498393
Invest New Drugs. 2013 Oct;31(5):1207-16
23397499
Oncologist. 2007 May;12 (5):577-83
17522246
J Transl Med. 2014 Apr 30;12:108
24884643
Science. 2011 Mar 25;331(6024):1565-70
21436444
Clin Cancer Res. 2009 Feb 1;15(3):1086-95
19188184
Immunol Rev. 2011 Jan;239(1):27-44
21198663
Ann Surg Oncol. 2014 Nov;21(12):3931-7
24943235
Crit Rev Oncol Hematol. 2015 Apr;94(1):31-44
25577571
Nat Rev Immunol. 2012 Mar 22;12(4):269-81
22437939
N Engl J Med. 2013 Apr 18;368(16):1509-18
23527958
J Clin Oncol. 2010 Jul 20;28(21):3485-90
20498386
J Clin Oncol. 2011 Mar 1;29(7):917-24
21282551
Clin Cancer Res. 2005 Feb 15;11(4):1474-82
15746049
Cancer Immunol Immunother. 2015 Sep;64(9):1083-93
25990075
Clin Cancer Res. 2008 Aug 1;14 (15):4843-9
18676757
N Engl J Med. 2010 Aug 19;363(8):711-23
20525992
J Natl Cancer Inst. 2008 Jul 2;100(13):950-61
18577748
Viruses. 2011 Jun;3(6):920-40
21994762
N Engl J Med. 2013 Jul 11;369(2):134-44
23724846
Curr Opin Genet Dev. 2008 Feb;18(1):11-8
18308558
World J Gastroenterol. 2013 Dec 14;19(46):8531-42
24379570
CA Cancer J Clin. 2013 Jan;63(1):11-30
23335087
Cancer Immunol Immunother. 2009 Jan;58(1):61-9
18488223
Oncology. 2010;78(3-4):237-48
20523084
J Clin Oncol. 2005 Feb 1;23(4):720-31
15613691
J Clin Oncol. 2014 Apr 1;32(10):1020-30
24590637
Cancer Immunol Immunother. 2002 Apr;51(2):99-106
11904734
Exp Ther Med. 2011 Jan;2(1):73-79
22977472
Nature. 2014 Nov 27;515(7528):558-62
25428503
Oncologist. 2007 Mar;12(3):356-61
17405901
World J Gastroenterol. 2014 Feb 28;20(8):1910-22
24616568
Clin Cancer Res. 2002 Jul;8(7):2044-51
12114402
J Immunol. 2000 Nov 15;165(10):5713-9
11067929
Oncology (Williston Park). 2014 Nov;28 Suppl 3:30-8
25384885
J Clin Oncol. 2003 Feb 15;21(4):624-30
12586798
Vaccine. 2007 Feb 19;25(9):1607-18
17166639
Eur J Cancer. 1991;27(6):703-10
1829908
J Clin Oncol. 2011 Jul 1;29(19):2667-74
21632509
Discov Med. 2013 May;15(84):301-8
23725603
N Engl J Med. 2009 Apr 2;360(14):1408-17
19339720
Cancer Gene Ther. 2002 Feb;9(2):202-8
11857039
Biomed Res Int. 2015;2015:605478
26161407
N Engl J Med. 2015 Jun 25;372(26):2509-20
26028255
J Clin Oncol. 2003 Sep 1;21(17):3343-50
12947071
Cancer Immunol Immunother. 2010 May;59(5):759-67
19943047
Cancer Immunol Res. 2014 Jul;2(7):632-42
24838938
N Engl J Med. 2012 Jun 28;366(26):2455-65
22658128
PLoS One. 2015 Jun 17;10(6):e0128911
26083022
J Gastrointest Oncol. 2015 Apr;6(2):208-23
25830040
Vaccines (Basel). 2012 Aug 24;1(1):1-16
26343847
Clin Cancer Res. 2001 Dec;7(12):3950-62
11751487
Nat Med. 1998 Mar;4(3):328-32
9500607
Nat Med. 1997 May;3(5):558-61
9142127